← Leaderboards
David M. Margolis
University Of Texas Sw Med Ctr/Dallas
$89,256,801
Attributed
$91,145,119
Total exposure
19
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $13.1M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$130,611,562 · 20
By mechanism
U19$52,207,856 · 4
UM1$49,395,952 · 2
R01$13,126,989 · 5
U01$12,034,650 · 3
T32$2,284,424 · 1
R56$1,232,322 · 3
Top collaborators
- Catherine Mary Bollard5 shared
Most similar at University Of Texas Sw Med Ctr/Dallas
Same institution · by research overlap
- J. Victor Garcia-Martinez$43,335,545
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsAntiretroviral TherapyInfectionCellsHiv-1ViralCd4 Positive T LymphocytesT-LymphocyteIn VivoLatent InfectionBaseBiological ModelsVirus DiseasesRestResearch PersonnelViremiaFutureCollaboratoryHistone Deacetylase InhibitorIn VitroPharmaceutical PreparationsComplexResponseSuccess
Grant awards (84)
Collaboratory of AIDS Researchers for Eradication (CARE)$5,246,834
UM1 · FY2025 · AI · contact PI
Collaboratory of AIDS Researchers for Eradication (CARE)$5,246,834
UM1 · FY2024 · AI · contact PI
Collaboratory of AIDS Researchers for Eradication (CARE)$5,246,834
UM1 · FY2023 · AI · contact PI
Collaboratory of AIDS Researchers for Eradication (CARE)$5,246,834
UM1 · FY2022 · AI · contact PI
Collaboratory of AIDS Researchers for Eradication (CARE)$5,246,834
UM1 · FY2021 · AI · contact PI
Collaboratory of AIDS Researchers for Eradication (CARE)$4,592,950
UM1 · FY2020 · AI · contact PI
HIV-specific ex-vivo expanded T cell therapy (HXTC) to Deplete the Latent Reservoir of Persistent HIV Infection$735,324
R01 · FY2020 · HL · contact PI
HIV Cure SWG: UNC CFAR$14,392
P30 · FY2020 · AI · contact PI
Collaboratory of AIDS Researchers for Eradication (CARE)$4,789,982
UM1 · FY2019 · AI · contact PI
A Pilot Trial of the effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection$1,355,943
U01 · FY2019 · AI · contact PI
HIV-specific ex-vivo expanded T cell therapy (HXTC) to Deplete the Latent Reservoir of Persistent HIV Infection$735,324
R01 · FY2019 · HL · contact PI
HIV Cure SWG: UNC CFAR$147,951
P30 · FY2019 · AI · contact PI
Collaboratory of AIDS Researchers for Eradication (CARE)$4,592,950
UM1 · FY2018 · AI · contact PI
A Pilot Trial of the effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection$1,348,882
U01 · FY2018 · AI · contact PI
HIV-specific ex-vivo expanded T cell therapy (HXTC) to Deplete the Latent Reservoir of Persistent HIV Infection$735,214
R01 · FY2018 · HL · contact PI
Infectious Disease Pathogenesis Research Training$238,453
T32 · FY2018 · AI · contact PI
HIV Cure SWG: UNC CFAR$19,110
P30 · FY2018 · AI · contact PI
Collaboratory of AIDS Researchers for Eradication (CARE)$4,592,950
UM1 · FY2017 · AI · contact PI
A Pilot Trial of the effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection$1,351,542
U01 · FY2017 · AI · contact PI
HIV-specific ex-vivo expanded T cell therapy (HXTC) to Deplete the Latent Reservoir of Persistent HIV Infection$770,866
R01 · FY2017 · HL · contact PI
Infectious Disease Pathogenesis Research Training$257,585
T32 · FY2017 · AI · contact PI
HIV Cure SWG: UNC CFAR$18,585
P30 · FY2017 · AI · contact PI
Collaboratory of AIDS Researchers for Eradication (CARE)$4,592,950
UM1 · FY2016 · AI · contact PI
A Pilot Trial of the effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection$1,348,882
U01 · FY2016 · AI · contact PI
HIV-specific ex-vivo expanded T cell therapy (HXTC) to Deplete the Latent Reservoir of Persistent HIV Infection$799,908
R01 · FY2016 · HL · contact PI
Infectious Disease Pathogenesis Research Training$287,695
T32 · FY2016 · AI · contact PI
HIV Cure SWG: UNC CFAR$18,331
P30 · FY2016 · AI · contact PI
Martin Delaney Collaboratory to Eradicate HIV-1 Infection$7,096,518
U19 · FY2015 · AI · contact PI
A Pilot Trial of the effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection$1,421,482
U01 · FY2015 · AI · contact PI
Studies in humans to delineate the basis for viral persistence$690,359
U19 · FY2015 · AI · contact PI
The Role of Gamma Delta T Cells as Persistent Reservoirs of HIV Infection$498,930
R56 · FY2015 · AI · contact PI
Administrative Core$405,630
U19 · FY2015 · AI · contact PI
Infectious Disease Pathogenesis Research Training$287,704
T32 · FY2015 · AI · contact PI
Martin Delaney Collaboratory to Eradicate HIV-1 Infection$8,513,331
U19 · FY2014 · AI · contact PI
Studies in humans to delineate the basis for viral persistence$2,209,658
U19 · FY2014 · AI · contact PI
Administrative Core$667,061
U19 · FY2014 · AI · contact PI
HIV Latency, Epigenetics, and Therapeutics$597,641
R01 · FY2014 · DA · contact PI
Infectious Disease Pathogenesis Research Training$262,961
T32 · FY2014 · AI · contact PI
Martin Delaney Collaboratory to Eradicate HIV-1 Infection$8,486,371
U19 · FY2013 · AI · contact PI
Studies in humans to delineate the basis for viral persistence$2,195,844
U19 · FY2013 · AI · contact PI
Administrative Core$938,966
U19 · FY2013 · AI · contact PI
HIV Latency, Epigenetics, and Therapeutics$580,859
R01 · FY2013 · DA · contact PI
A Phase II/II Investigation of the Effect of Vorinostat (VOR) in HIV Infection$531,261
U01 · FY2013 · AI · contact PI
Nanocrystal delivery to the CNS to improve HIV therapy$325,629
R01 · FY2013 · MH · contact PI
Martin Delaney Collaboratory to Eradicate HIV-1 Infection$8,990,073
U19 · FY2012 · AI · contact PI
Studies in humans to delineate the basis for viral persistence$1,802,930
U19 · FY2012 · AI · contact PI
HIV Latency, Epigenetics, and Therapeutics$611,361
R01 · FY2012 · DA · contact PI
A Phase II/II Investigation of the Effect of Vorinostat (VOR) in HIV Infection$565,171
U01 · FY2012 · AI · contact PI
Administrative Core$546,507
U19 · FY2012 · AI · contact PI
Nanocrystal delivery to the CNS to improve HIV therapy$339,395
R01 · FY2012 · MH · contact PI
Infectious Disease Pathogenesis Research Training$193,305
T32 · FY2012 · AI · contact PI
Martin Delaney Collaboratory to Eradicate HIV-1 Infection$6,380,150
U19 · FY2011 · AI · contact PI
HIV Latency, Epigenetics, and Therapeutics$618,573
R01 · FY2011 · DA · contact PI
A Phase II/II Investigation of the Effect of Vorinostat (VOR) in HIV Infection$565,455
U01 · FY2011 · AI · contact PI
Nanocrystal delivery to the CNS to improve HIV therapy$339,138
R01 · FY2011 · MH · contact PI
Studies in humans to delineate the basis for viral persistence$300,048
U19 · FY2011 · AI · contact PI
Administrative Core$299,336
U19 · FY2011 · AI · contact PI
Infectious Disease Pathogenesis Research Training$206,161
T32 · FY2011 · AI · contact PI
Innovative therapies to elimate persistent HIV Infection$1,330,537
U19 · FY2010 · AI · contact PI
HIV Latency, Epigenetics, and Therapeutics$637,614
R01 · FY2010 · DA · contact PI
Mechanisms of chromatin regulation that drive HIV latency$404,892
R56 · FY2010 · AI · contact PI
Nanocrystal delivery to the CNS to improve HIV therapy$342,751
R01 · FY2010 · MH · contact PI
Infectious Disease Pathogenesis Research Training$100,298
T32 · FY2010 · AI · contact PI
Innovative therapies to elimate persistent HIV Infection$1,354,537
U19 · FY2009 · AI · contact PI
Nanocrystal delivery to the CNS to improve HIV therapy$354,668
R01 · FY2009 · MH · contact PI
Infectious Disease Pathogenesis Research Training$226,038
T32 · FY2009 · AI · contact PI
The in vivo effect of HDAC Inhibitors on HIV gene expression in resting CD4+ T Ce$111,000
R34 · FY2009 · AI · contact PI
Infectious Disease Pathogenesis Research Training$224,224
T32 · FY2008 · AI · contact PI
Clearing Persistently HIV-Infected CD4+ T Lymphocytes$37,170
R01 · FY2008 · AI · contact PI
Clearing Persistently HIV-Infected CD4+ T Lymphocytes$642,138
R01 · FY2007 · AI · contact PI
Repression of HIV Transcription: from mechanism to anti-latency therapies$328,500
R56 · FY2007 · AI · contact PI
Clearing Persistently HIV-Infected CD4+ T Lymphocytes$658,903
R01 · FY2006 · AI · contact PI
Repression of HIV Transcription-A Pathway to Quiescence$320,781
R01 · FY2006 · AI · contact PI
Clearing Persistently HIV-Infected CD4+ T Lymphocytes$685,184
R01 · FY2005 · AI
Repression of HIV Transcription-A Pathway to Quiescence$351,000
R01 · FY2005 · AI
Clearing Persistently HIV-Infected CD4+ T Lymphocytes$45,724
R01 · FY2005 · AI
Repression of HIV Transcription-A Pathway to Quiescence$461,994
R01 · FY2004 · AI
U.T. SOUTHWESTERN ADULT AIDS CLINICAL TRIALS UNIT$1,380,842
U01 · FY2003 · AI
Repression of HIV Transcription-A Pathway to Quiescence$467,688
R01 · FY2003 · AI
U.T. SOUTHWESTERN ADULT AIDS CLINICAL TRIALS UNIT$1,232,598
U01 · FY2002 · AI
Repression of HIV Transcription-A Pathway to Quiescence$315,900
R01 · FY2002 · AI
U.T. SOUTHWESTERN ADULT AIDS CLINICAL TRIALS UNIT$932,592
U01 · FY2001 · AI
REPRESSION OF HIV TRANSCRIPTION--A PATHWAY TO QUIESCENCE$368,876
R01 · FY2001 · AI
REPRESSION OF HIV TRANSCRIPTION--A PATHWAY TO QUIESCENCE$247,366
R01 · FY2000 · AI